Inventor · disambiguated record
Na Guo
Also filed as: GUO NA
4 granted patents·5 pending applications·9 citations·filing 2011–2023
62Inventor score
Files withSHANGHAI ZHEYE BIOTECHNOLOGY CO LTD3CHENGDU DI AO PHARMACEUTICAL GROUP CO LTD2BGI SHENZHEN1JI JIANXIN1TIANJIN UNIV OFR SCIENCE AND TECHNOLOGY1
Top patents by PatentIndex Score
9 records- 0180US9187430B2Poly (ADP-ribose) polymerase inhibitorCHENGDU DI AO PHARMACEUTICAL GROUP CO LTD·Filed 2012·Granted Nov 17, 2015·9 cites·2 claims
- 0252US2023159529A1Aromatic compound and application thereof in antitumor drugSHANGHAI ZHEYE BIOTECHNOLOGY CO LTD·Filed 2023·Application pending·0 cites
- 0350US2021340509A1Reverse transcriptase with increased enzyme activity and application thereofBGI SHENZHEN·Filed 2021·Application pending·0 cites
- 0442US2023365610A1Aryl Glucoside DerivativeSHANGHAI ZHEYE BIOTECHNOLOGY CO LTD·Filed 2020·Application pending·0 cites
- 0542US2023331761A1Aryl Glucoside Derivative, Preparation Method Therefor And Application ThereofSHANGHAI ZHEYE BIOTECHNOLOGY CO LTD·Filed 2020·Application pending·0 cites
- 0640US2021093729A1Preparation and application of surface double modified human serum albumin as targeting nano drug carrierTIANJIN UNIV OFR SCIENCE AND TECHNOLOGY·Filed 2020·Application pending·0 cites
- 0737US9718787B2Poly (ADP-ribose) polymerase inhibitorCHENGDU DI'AO PHARMACEUTICAL GROUP CO LTD·Filed 2015·Granted Aug 1, 2017·0 cites·10 claims
- 0833US8940890B2Preparation method of 5-[[2(R)-[1(R)-[3,5-bis(trifluoromethyl) phenyl]ethoxy]-3(S)-4-fluorophenyl-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-oneJI JIANXIN·Filed 2011·Granted Jan 27, 2015·0 cites·18 claims
- 0931US11413281B2Ternary conjugate of antitumor drug, and synthesis and applicationUNIV TIANJIN SCIENCE & TECH·Filed 2016·Granted Aug 16, 2022·0 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when Na Guo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →